Back to today’s briefing

Story perspectives

FDA Panel Approves Compounding Pathway for Six Peptides

8/3/2026

44 8 Full Breakdown

Summary

Story summary

The FDA panel voted to permit compounding six peptide therapies.
HHS Secretary Robert F. Kennedy Jr. urged the FDA to provide the peptides through inspected facilities.
Panelist Mohammed, a peptide seller, said the vote creates a regulated pathway for current patients.
Former FDA official Ilisa Bernstein warned the agency must follow data to avoid risks, noting attorney Abha Kundi said the FDA could face lawsuits if it rejects the recommendation.

1 of 1

Story summary

The FDA panel voted to permit compounding six peptide therapies.
HHS Secretary Robert F. Kennedy Jr. urged the FDA to provide the peptides through inspected facilities.
Panelist Mohammed, a peptide seller, said the vote creates a regulated pathway for current patients.
Former FDA official Ilisa Bernstein warned the agency must follow data to avoid risks, noting attorney Abha Kundi said the FDA could face lawsuits if it rejects the recommendation.